Fortis Healthcare

    FORTIS
    Pharma
    ₹887.80
    price as of 11/9/2026, 5:28:13 pm

    Market cap ₹67,025 Cr

    P/E
    63.87
    Day range
    ₹885.00 – ₹900.00
    52-week range
    ₹766.80 – ₹1,104.30
    Volume
    7.85 L
    Open
    ₹897.50
    Prev close
    ₹902.45
    Promoters pledged 4.3% of their shares
    52-week range, adjusted for splits and bonuses
    ₹766.8₹1,104.3
    2 Apr 202617 Oct 2025
    Index membership & F&O
    NIFTY 200NIFTY 500NIFTY MIDCAP 150NIFTY HEALTHCAREF&O lot 775

    Price history

    6M change +0.75%RSI (14) 38.0 NeutralSMA 20 · 50 overlaid

    Price & delivery on the exchange

    NSE bhavcopy to 11 Sept 2026 · delivery 45.2% today vs 54.1% average · BSE close ₹887.3

    1 Apr23 Apr15 May5 Jun24 Jun15 Jul3 Aug21 Aug11 Sept₹780₹840₹900₹960₹1,0200%25%50%75%100%
    • Delivery
    • NSE close
    • BSE close

    High delivery with a rising price suggests buyers holding rather than trading the move.

    Futures & options

    NSE F&O close, 11 Sept 2026 · options expiring 29 Sept 2026

    Short build-up
    Near-month future
    ₹892.25
    Change
    -1.13%
    Basis over spot
    +₹4.45
    Futures OI (shares)
    1.22 Cr
    OI change
    +2.23%
    Put-call ratio
    0.89
    Max pain
    ₹910
    Resistance (call OI)
    ₹900
    Support (put OI)
    ₹900
    Lot size
    775

    Open interest by strike

    Calls open above (resistance) and puts below (support), in shares

    76080082084086088090092094096098010001020104010601100080,0001.6 L2.4 L3.2 Lspot
    • Call OI
    • Put OI

    Futures open interest and price

    Near-month future, day by day since collection began

    The daily history builds from each close.

    Key metrics

    P/E (TTM)
    69.0
    EPS (TTM)
    ₹13.88
    Price / Book
    6.98
    ROE (FY26)
    11.3%
    ROCE (latest year)
    13%
    Dividend yield
    0.11%
    Net margin (TTM)
    11.3%
    Current ratio
    0.86
    Debt / Equity
    0.30
    Revenue growth (5y)
    17.8%

    Moving averages (NSE)

    Simple moving averages of the NSE price, and where the last price sits against each
    5-day10-day20-day50-day100-day300-day
    ₹911.1Price below₹913.37Price below₹913.57Price below₹937.19Price below₹945.79Price below₹913.31Price below

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +13.2%
    Profit 3Y CAGR
    +18.9%
    Revenue YoY (Jun 2026)
    +17.4%
    Profit YoY (Jun 2026)
    +2.2%
    Operating margin
    21.0%
    Net margin
    10.7%

    Revenue, profit & margin - quarterly

    Bars in ₹ crore (a loss shows red); line is operating margin

    Sep 2023Mar 2024Sep 2024Mar 2025Sep 2025Jun 20260 Cr650 Cr1.3K Cr1.9K Cr2.6K Cr0%6%12%18%24%
    • Revenue
    • Net profit
    • Operating margin

    Who owns the company

    Shareholding as of Jun 2026

    • DII
    • Promoter
    • FII
    • Public

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-5.0K Cr-2.5K Cr0 Cr2.5K Cr5.0K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26-22%-11%0%11%22%15%

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); line is debt-to-equity

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 20260 Cr2.5K Cr5.0K Cr7.5K Cr10.0K Cr0.0x0.1x0.3x0.5x0.6x
    • Equity
    • Debt
    • Debt / equity

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
    Sales1,7701,6801,7861,8591,9881,9282,0072,1672,3312,2652,3652,545
    Expenses1,4401,3961,4051,5161,5541,5531,5721,6761,7751,7591,8322,008
    Operating Profit330284381343435375435491556506532537
    OPM %19%17%21%18%22%19%22%23%24%22%23%21%
    Other Income18191714-4247-293150-34-228
    Interest323335353645687075868480
    Depreciation848792919597102101106120122122
    Profit before tax233183271230261279237351425266324363
    Tax %21%27%25%24%26%9%21%24%23%26%16%25%
    Net Profit184134203174193254188267329197271273
    EPS in Rs₹2.30₹1.78₹2.37₹2.20₹2.34₹3.28₹2.44₹3.45₹4.26₹2.57₹3.52₹3.53

    From company filings, updated 11 Sept 2026. Consolidated figures where the company reports them.Information only, not investment advice.

    Strengths, risks & growth

    FHL was incorporated in February 1996. The company’s first healthcare facility became operational in Mohali, Punjab in 2001. It is a leading integrated healthcare service provider in India. The healthcare verticals of the company primarily comprise hospitals, diagnostics and day care specialty facilities. Currently, the company operates its healthcare delivery services in India, Nepal, Dubai and Sri Lanka with 36 healthcare facilities with approximately 4,000 operational beds. [1] Company controls its diagnostics business through its 57% owned subsidiary SRL Limited. It is amongst the largest private diagnostics chains. It has a presence in over 600 cities and towns, with an established strength of 415 laboratories, 8,200 direct clients and 1,400 Collection Centers. [2]

    Strengths

    • Company has delivered good profit growth of 64.3% CAGR over last 5 years

    Risks

    • Stock is trading at 6.77 times its book value
    • Company has a low return on equity of 9.87% over last 3 years.

    Compounded Sales Growth

    10 Years
    +8%
    5 Years
    +18%
    3 Years
    +13%
    TTM
    +18%

    Compounded Profit Growth

    10 Years
    +60%
    5 Years
    +64%
    3 Years
    +27%
    TTM
    +16%

    Stock Price CAGR

    10 Years
    +18%
    5 Years
    +26%
    3 Years
    +38%
    1 Year
    -8%

    Return on Equity

    10 Years
    +5%
    5 Years
    +9%
    3 Years
    +10%
    Last Year
    +11%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderSept 2025Dec 2025Mar 2026Jun 2026Change
    Promoter31.17%31.17%31.17%31.17%0.00 pp
    FII27.90%27.84%25.98%25.20%-0.78 pp
    DII29.14%29.33%31.35%32.23%+0.88 pp
    Public11.79%11.65%11.50%11.40%-0.10 pp

    Filed with NSE for Jun 2026: promoters 31.17%, public 68.83% · XBRL filing

    Analysts & fund holdings

    90%
    90% recommend buy
    20 analysts cover the stock
    Valuation vs Health Care Providers & Services
    P/E63.9 vs 46.4
    Sector P/B5.84
    Beta1.20

    Who holds the shares, quarter by quarter

    Mutual funds 25.81% (+0.09 pp)
    Mar 25
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    • Promoters31.2%
    • Foreign institutions25.2%
    • Mutual funds25.8%
    • Insurance4.6%
    • Other domestic institutions1.8%
    • Retail3.3%
    • Others8.1%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    HDFC Mid Cap Fund4.25%2.69%-0.39 pp
    Kotak Mid Cap Fund3.88%3.83%-0.25 pp
    Nippon India Growth Mid Cap Fund1.99%2.61%-0.05 pp
    Axis Midcap Fund1.66%3.21%-0.34 pp
    DSP Midcap Fund0.83%2.77%+0.06 pp

    Scorecard

    Performance
    Avg
    Valuation
    High
    Growth
    Avg
    Profitability
    High
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Parasram India.

    Corporate actions

    • dividend
      Not available — not reported in this filing

      Dividend - Re 1 Per Share

      24 Jul 2026
      ex-date
    • dividend
      Not available — not reported in this filing

      Dividend - Re 1 Per Share

      25 Jul 2025
      ex-date
    • dividend
      Not available — not reported in this filing

      Dividend - Re 1 Per Share

      24 Jul 2024
      ex-date
    • dividend
      Not available — not reported in this filing

      Dividend - Re 1 Per Share

      20 Jul 2023
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      16 Sept 2016
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      14 Sept 2015
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      18 Sept 2014
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      19 Sept 2013
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      21 Sept 2012
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      12 Sept 2011
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      13 Sept 2010
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      22 Sept 2009
      ex-date
    • other
      Not available — not reported in this filing

      Rhts Eq 2:5 & 2 Wrnt:2 Eq

      18 Aug 2009
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      10 Sept 2008
      ex-date
    • other
      Not available — not reported in this filing

      Agm

      19 Sept 2007
      ex-date

    Company announcements

    Company Update
    Update On Material Litigation Filed By Northern TK Venture Pte Ltd. ('NTK'), The Promoter Shareholder Of The Company, Against Daiichi Sankyo Company, Limited Before The Tokyo District Court In Japan.

    The relevant disclosure is attached.

    Company Update
    Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    The relevant disclosure is attached.

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    The revised Intimation is attached.

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    The revised Intimation is attached.

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    The relevant disclosure is attached

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    The relevant disclosre is attached.

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    The Relevant disclosure is attached.

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    The Relevant Disclosure is Attached.

    Company Update
    Announcement Under Regulation 30 (LODR) - Regarding Order Passed By The Hon'Ble Delhi High Court In Relation To Certain Applications Filed By Daiichi Sankyo Company, Limited Inter Alia The Company. Detailed Disclosure Is Attached.

    Relevant disclosure is attached.

    Company Update
    ESG Rating

    The relevant disclosure is attached.

    Company Update
    Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    Relevant disclosure attached

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    Relevant disclosure attached

    AGM/EGMPrice-sensitive
    Summary Of The Proceedings Of The 30Th Annual General Meeting.

    The relevant disclosure is attached.

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Outcome of AGM

    Proceeding of 30th Annual General Meeting

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Relevant disclosure is attached

    Filed with BSE (scrip 532843); the last 45 days. Documents open at bseindia.com.

    SEBI filings & orders

    From SEBI's website. An order may concern the company, its officers or trading in its shares, and may be under appeal - read the order itself. Personal identifiers are withheld.

    Buybacks, open offers & rights issues

    Regulatory orders

    • Adjudication order

      Adjudication Order in the matter of Fortis Healthcare Ltd Corrigendum

      18 May 2022
      Read on SEBI
    • Final order

      Final Order in the matter of Fortis Healthcare Ltd.

      19 Apr 2022
      Read on SEBI
    • Settlement order

      Settlement order in respect of Mr. Vishal Bali in the matter of Fortis Healthcare Limited

      21 Feb 2022
      Read on SEBI
    • Settlement order

      Settlement order in respect of Mr Aditya Vij, Mr Sandeep Puri, Mr Balinder Singh Dhillon and Religare Finvest Limited in the matter of Fortis Healthcare Limited

      31 Jan 2022
      Read on SEBI
    • Adjudication order

      Adjudication Order in respect of Mr. Rashim Tandon, Partner, Deloitte Haskins and Sells LLP, in the matter of Fortis Healthcare Limited

      26 Aug 2021
      Read on SEBI

    Documents

    Annual reports

    Earnings calls

    Credit ratings

    Documents open at BSE or the rating agency that issued them.